Abstract
Intravenous thrombolytic treatment represents the gold standard for acute ischemic stroke treatment. However there is some concern to perform this treatment in patients with known cardiac myxomas for the risk of haemorragic complications. Here we described a 63-year-old patient with ischemic stroke due to embolization of atrial myxoma and treated with intravenous recombinant tissue plasminogen activator alteplase. The patient did not show improvement after treatment; 25 days later a brain CT showed an asymptomatic small hemorrhagic infarction, probably due to the large size of ischemic lesion. The lack of response might be explained by the embolization of a large tumor fragment. One-year after cardiac surgery clinical follow-up did not reveal new neurological signs nor symptoms. This case report suggests that systemic thrombolysis is a safe procedure also in patient with atrial myxoma. The efficacy of therapy seems to be related to embolus composition.
Keywords: Stroke, atrial myxoma, thrombolysis, Intravenous thrombolytic treatment, cardiac myxomas, haemorragic complications, intravenous recombinant tissue plasminogen activator alteplase, ischemic lesion
Current Drug Safety
Title: Safety of Intravenous Thrombolysis in Ischemic Stroke Caused by Left Atrial Myxoma
Volume: 6 Issue: 5
Author(s): Maurizio Acampa, Rossana Tassi, Francesca Guideri, Giovanna Marotta, Lucia Monti, Gianni Capannini, Alfonso Cerase and Giuseppe Martini
Affiliation:
Keywords: Stroke, atrial myxoma, thrombolysis, Intravenous thrombolytic treatment, cardiac myxomas, haemorragic complications, intravenous recombinant tissue plasminogen activator alteplase, ischemic lesion
Abstract: Intravenous thrombolytic treatment represents the gold standard for acute ischemic stroke treatment. However there is some concern to perform this treatment in patients with known cardiac myxomas for the risk of haemorragic complications. Here we described a 63-year-old patient with ischemic stroke due to embolization of atrial myxoma and treated with intravenous recombinant tissue plasminogen activator alteplase. The patient did not show improvement after treatment; 25 days later a brain CT showed an asymptomatic small hemorrhagic infarction, probably due to the large size of ischemic lesion. The lack of response might be explained by the embolization of a large tumor fragment. One-year after cardiac surgery clinical follow-up did not reveal new neurological signs nor symptoms. This case report suggests that systemic thrombolysis is a safe procedure also in patient with atrial myxoma. The efficacy of therapy seems to be related to embolus composition.
Export Options
About this article
Cite this article as:
Acampa Maurizio, Tassi Rossana, Guideri Francesca, Marotta Giovanna, Monti Lucia, Capannini Gianni, Cerase Alfonso and Martini Giuseppe, Safety of Intravenous Thrombolysis in Ischemic Stroke Caused by Left Atrial Myxoma, Current Drug Safety 2011; 6 (5) . https://dx.doi.org/10.2174/157488611798918665
DOI https://dx.doi.org/10.2174/157488611798918665 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |

- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Neurocysticercosis: The Enigmatic Disease
Central Nervous System Agents in Medicinal Chemistry Evaluation of Coronary Artery Diffuse Calcification Stenosis by Corrected Coronary Opacification Difference
Current Medical Imaging Lessons from the REACH Registry in Europe
Current Vascular Pharmacology Heart Failure in Acute Ischemic Stroke
Current Cardiology Reviews Models to Study Atherosclerosis: A Mechanistic Insight
Current Vascular Pharmacology Mechanosensitive Channels: Therapeutic Targets in the Myocardium?
Current Pharmaceutical Design Early Timing of Endovascular Treatment for Aneurysmal Subarachnoid Hemorrhage Achieves Improved Outcomes
Current Neurovascular Research Endothelial Remodelling and Intracellular Calcium Machinery
Current Molecular Medicine Unraveling the Action Mechanism of Buyang Huanwu Tang (BYHWT) for Cerebral Ischemia by Systematic Pharmacological Methodology
Combinatorial Chemistry & High Throughput Screening Novel Aspects in the Pathophysiology of Peripheral Vasculopathy in Systemic Sclerosis
Current Rheumatology Reviews Meet Our Co-Editor
Cardiovascular & Hematological Agents in Medicinal Chemistry Cerebral Aneurysm as an Exacerbating Factor in Stroke Pathology and a Therapeutic Target for Neuroprotection
Current Pharmaceutical Design Calcium Channel Blockers - Benefits Upon Vascular Biology in Hypertensive Patients
Cardiovascular & Hematological Agents in Medicinal Chemistry Injecting Illicit Substances Epidemic and Infective Endocarditis
Infectious Disorders - Drug Targets Dealing with the Substance Abuse Epidemic and Infective Endocarditis:Clinical, Immunologic and Pathogenetic Aspects
Current Vascular Pharmacology Anatomical Approach to Clinical Problems of Popliteal Fossa
Current Rheumatology Reviews The Obesity-associated Risk in Open and Endovascular Repair of Abdominal Aortic Aneurysm
Current Pharmaceutical Design A Review of Pediatric Mediastinal Masses and Castlemans Disease
Current Pediatric Reviews In vivo Optical Molecular Imaging of Cardiovascular Diseases: Long Road Ahead
Current Molecular Imaging (Discontinued) Thrombolytic Treatment of Cardiac Myxoma-Induced Ischemic Stroke: A Review
Current Drug Safety